Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
A Micron five-year double thesis focused on HBM demand, DRAM/NAND cycle discipline, capital intensity, and whether AI memory improves through-cycle economics.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
A refreshed Micron Technology thesis using latest official May 2026 data, Q2 FY2026 results, HBM4 production, AI server memory demand, data-center mix, U.S. manufacturing updates, capex, balance-sheet strength, and cycle risk.
OpenADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
OpenSEC filings, financial facts, source resources, and Goglides workspace context for ADC Therapeutics SA.
OpenA TSMC five-year double thesis focused on advanced-node foundry leadership, advanced packaging, AI customer demand, capex, margins, and Taiwan risk.
OpenA Coverage Bootstrap TSMC company evaluation covering advanced-node foundry leadership, CoWoS, customers, margins, capex, global fabs, Taiwan risk, and valuation setup.
OpenA filing-led NVDA five-year double thesis focused on data-center demand, CUDA lock-in, networking attach, margin durability, and valuation risk.
OpenA Coverage Bootstrap NVIDIA company evaluation covering AI accelerators, CUDA, networking, data-center concentration, margins, export controls, valuation risk, and proof gates.
OpenA Broadcom five-year double thesis focused on custom AI silicon, Ethernet networking, VMware free cash flow, customer concentration, and integration risk.
OpenA Coverage Bootstrap Broadcom company evaluation covering custom AI silicon, Ethernet networking, VMware, free cash flow, customer concentration, integration risk, and valuation discipline.
OpenAn ASML five-year double thesis focused on EUV scarcity, High-NA adoption, China/export-control risk, bookings visibility, and semiconductor capex cycles.
OpenA Coverage Bootstrap ASML company evaluation covering the business model, EUV and DUV products, customers, moat, financial quality, export-control risk, valuation setup, and watchlist triggers.
OpenAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAeva has the kind of customer list lidar startups chase: Daimler Truck, a Top 10 European OEM, NVIDIA, Forterra, Nikon and smart-infrastructure deployments. The catch is that revenue is still $6.3 million a quarter, broad-based deliveries are not expected in 2
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenADI is not a pure AI stock. It is a cash-rich analog semiconductor leader where industrial recovery, automotive resilience, and data-center infrastructure orders are now arriving at the same time.
OpenAdagene is trying to turn SAFEbody antibody masking into a broader immuno-oncology platform. The hook is muzastotug's early dose-dependent signal; the catch is that randomized proof, partner execution, and financing still decide the stock.
OpenActuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAxcelis has a focused ion-implant franchise, a sizable installed-base service layer, strong cash and investment liquidity, and Veeco optionality. The hard part is that power and mature-node digestion have pulled revenue down, backlog is lower, export controls
OpenOfficial-source baseline for Ascentage Pharma using SEC submissions, FY2025 Form 20-F, SEC companyfacts, company-filed FY2025 results releases, ASCO 2026 update, annual meeting materials, and oncology peer filings.
OpenTag facets appear after tag usage counts are rebuilt.